BioNTech SE Statistics
Total Valuation
BioNTech SE has a market cap or net worth of $27.11 billion. The enterprise value is $10.94 billion.
Important Dates
The last earnings date was Monday, August 4, 2025, before market open.
| Earnings Date | Aug 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BioNTech SE has 240.40 million shares outstanding. The number of shares has increased by 0.29% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 240.40M |
| Shares Change (YoY) | +0.29% |
| Shares Change (QoQ) | +0.53% |
| Owned by Insiders (%) | 18.34% |
| Owned by Institutions (%) | 23.25% |
| Float | 93.81M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.03 |
| Forward PS | 15.19 |
| PB Ratio | 1.25 |
| P/TBV Ratio | 1.39 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.24 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.61, with a Debt / Equity ratio of 0.01.
| Current Ratio | 8.61 |
| Quick Ratio | 8.37 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -42.71 |
Financial Efficiency
Return on equity (ROE) is -1.84% and return on invested capital (ROIC) is -2.47%.
| Return on Equity (ROE) | -1.84% |
| Return on Assets (ROA) | -2.14% |
| Return on Invested Capital (ROIC) | -2.47% |
| Return on Capital Employed (ROCE) | -3.80% |
| Revenue Per Employee | $499,171 |
| Profits Per Employee | -$59,795 |
| Employee Count | 6,772 |
| Asset Turnover | 0.13 |
| Inventory Turnover | 2.04 |
Taxes
| Income Tax | -50.97M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +39.89% in the last 52 weeks. The beta is 1.24, so BioNTech SE's price volatility has been higher than the market average.
| Beta (5Y) | 1.24 |
| 52-Week Price Change | +39.89% |
| 50-Day Moving Average | 109.53 |
| 200-Day Moving Average | 108.66 |
| Relative Strength Index (RSI) | 56.40 |
| Average Volume (20 Days) | 697,960 |
Short Selling Information
| Short Interest | 6.05M |
| Short Previous Month | 6.03M |
| Short % of Shares Out | 6.55% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 9.51 |
Income Statement
In the last 12 months, BioNTech SE had revenue of $3.38 billion and -$404.93 million in losses. Loss per share was -$1.69.
| Revenue | 3.38B |
| Gross Profit | 2.70B |
| Operating Income | -882.80M |
| Pretax Income | -269.98M |
| Net Income | -404.93M |
| EBITDA | -579.80M |
| EBIT | -882.80M |
| Loss Per Share | -$1.69 |
Full Income StatementBalance Sheet
The company has $16.48 billion in cash and $316.62 million in debt, giving a net cash position of $16.17 billion or $67.26 per share.
| Cash & Cash Equivalents | 16.48B |
| Total Debt | 316.62M |
| Net Cash | 16.17B |
| Net Cash Per Share | $67.26 |
| Equity (Book Value) | 21.73B |
| Book Value Per Share | 90.40 |
| Working Capital | 16.53B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$2.04 billion and capital expenditures -$252.97 million, giving a free cash flow of -$2.29 billion.
| Operating Cash Flow | -2.04B |
| Capital Expenditures | -252.97M |
| Free Cash Flow | -2.29B |
| FCF Per Share | -$9.51 |
Full Cash Flow StatementMargins
Gross margin is 79.76%, with operating and profit margins of -26.12% and -11.98%.
| Gross Margin | 79.76% |
| Operating Margin | -26.12% |
| Pretax Margin | -13.49% |
| Profit Margin | -11.98% |
| EBITDA Margin | -17.15% |
| EBIT Margin | -26.12% |
| FCF Margin | n/a |
Dividends & Yields
BioNTech SE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.29% |
| Shareholder Yield | -0.29% |
| Earnings Yield | -1.49% |
| FCF Yield | -8.43% |
Dividend DetailsAnalyst Forecast
The average price target for BioNTech SE is $139.60, which is 23.78% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $139.60 |
| Price Target Difference | 23.78% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 18 |
| Revenue Growth Forecast (5Y) | 3.28% |
| EPS Growth Forecast (5Y) | -16.48% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioNTech SE has an Altman Z-Score of 6.41 and a Piotroski F-Score of 2.
| Altman Z-Score | 6.41 |
| Piotroski F-Score | 2 |